

tumors and a mitomycin C-resistant tumor in vitro and in vivo 89
 Twelves C → Dunkelman H
 Twelves CJ, Ash CM, Miles DW, Thomas DGT, Souhami RL: Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma 481
 Valdivieso M → Chabot GG
 Valeriote F → Brodfeuerer J
 van der Vijgh WJF → Leeuwenkamp OR
 van Tellingen O → Deurloo MJM
 Varnavas A → Sava G
 Verma S → Stewart DJ
 Venitt S → Brookes P
 Villacorte DG → Newman EM
 Vindelov L → Jensen PB
 Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J, Cooper MR, Coughlin KM, Green MR: Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B 239

Voth E → Rauschecker HF
 Vukas D → Kolaric K
 Wallis J → Jackson GH
 Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC Jr: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts 278
 Watanabe M → Nakajima T
 Watson JV → Smith PJ
 Waud WR, Harrison SD Jr, Gilbert KS, Laster R Jr, Griswold DP Jr: Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia 456
 Whitehouse E → Robbins MEC
 Wilkinson P → Logue J
 Willemze R → Colly LP
 Willenbrock C → Rauschecker HF
 Williams CJ → Coleman RE
 Wiltshaw E → Coleman RE
 Wold H → Gandara DR
 Wyrick SD → Carfagna PF

Xu Y-J, Li D-D, Zhen Y-S: Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells 41

Yamada N → Nakajima T
 Yamamoto M → Saito H
 Yokoyama K → Nakajima T
 Yerkow EJ, Laskin JD: Mechanism of action of psoralens: isobogram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic 315

Zeller WJ → Frühauf S
 Zhen Y-S → Xu Y-J
 Zorzet S → Sava G

Indexed in *Current Contents*

Subject index of volume 27

Adenocarcinoma 487
 Adriamycin 413
 Advanced breast cancer 101, 394, 477
 Advanced human breast cancer 326
 Advanced lung cancer 229
 Advanced non-small cell lung cancer 243
 Alkytating drugs 278
 Alveolitis 168
 Aminoglutethimide 101, 451
 Amsacrine 397
 Animal scale-up 20
 Anthracycline metabolism 147
 Antiemetic effect 472
 Antiestrogens 8
 Antimetastatic compound 423
 Antitumor activity 89, 194, 263
 Antitumor agent 295
 Antitumor biotic 41
 Antitumor effects 8, 429
 Ara-C 151
 Aromatase inhibitor 367
 Bioavailability 308
 Biochemical modulation 60
 Biodistribution 13
 Biotransformation 335
 Bleomycin 484
 Bone marrow transplantation 361
 Brain 1
 Breast cancer 79, 367, 409, 451
 Busulfan 226
 Carboplatin 229, 239, 409, 481, 484
 Carboplatin-based chemotherapy 234

Carboplatin/etoposide 389
 Carcinoma of the cervix 52
 Celipitum-induced nephrotoxicity 178
 Cell-cycle progression 464
 Cell density 417
 Cell differentiation 171
 Cell kinetics 121
 Cellular pharmacokinetics 320, 417
 Cerebellar toxicity 76
 Cervical carcinoma 484
 Chemotherapy 52, 72, 94, 385, 394, 413, 477
 Children 60, 164, 397
 2-Chloro-2',3'-dideoxyadenose 285
 Cimetidine 125
 cis-Dichloro-bis-isopropylamine platinum (II) 248
 Cisplatin 33, 52, 55, 111, 121, 131, 135, 211, 251, 347, 417, 464, 472
 Cisplatin-resistant P388 leukemia 456
 c-Myc expression 171
 Combination chemotherapy 81, 131, 251
 Combined modality treatment 94
 Comparative disposition 106
 Comparative effects 47
 Cross-resistance 456
 Cyclophosphamide 1, 125, 440
 Cytarabine 33, 60, 76, 151
 Cytosine arabinoside 141
 Cytotoxicity 41, 342, 440
 Dacarbazine 81
 Decarbazine pharmacokinetics 157
 1,2-diaminocyclohexaneplatinum(IV) 335

Difluorodeoxycytidine 2' 258
 Distribution 347
 DNA binding 248
 DNA polymerase 199
 Doxorubicin 47, 219
 Doxorubicinol 219
 Drug interaction 101
 Drug resistance 151
 Ecomustine 295
 ELISA 115
 Endocrinology 367
 Epidoxorubicin 4' 47
 Epipodophyllotoxin 194
 Epirubicin glucuronide 147
 Etoposide 115
 Feasibility 490
 Flavone acetic acid 27
 Flow-through system 320
 Fluorouracil 5- 79, 131, 320, 477
 Flutamide 401
 Fotemustine 81
 Fotemustine [¹⁴] 106
 Galactosidase 115
 Gastrointestinal lymphoma 385
 Gemcitabine 258
 Glioma 278
 Head and neck carcinoma 464
 Hepatic enzyme 226
 Hepatocytes 320
 Hepatoma BEL-7402 cells 41
 High-dose cisplatin 243
 High-dose epirubicin 394
 High-grade glioma 481
 Histidine 271

- HL-60 cells 171
 HO-221 199
 Hodgkin's disease 161
 Hoechst 33342 445
 Homocysteine 331
 HPLC 295
 Human tumour cells 445
 4-Hydroxyandrostenedione 67
 7-Hydroxymethotrexate 164
 Hydroxyurea 33, 168
- Idarubicin 308
 Ifosfamide 52, 251
 Imidazotetrazone 342
 Immunodeficiency virus-1 agent 285
 Inflammatory carcinoma 94
 Infusion 472
 Inoculum effect 417
 Interleukin-2 157
 Intraperitoneal chemotherapy 121
 Intrathecal chemotherapy 329
 Intratumoural drug administration 347
 Intratumoural slow release 135
 In vitro culture conditions 354
 Iproplatin 248, 481
 Isobogram analysis 315
- Kinetics 379
- Leakage 379
 Leucovorin 131
 Leukemia 141
 Limb 379
 Lipid peroxidation 178
 Liposomal doxorubicin 13
 Liposomes 429
 Lung 487
 Lymphoblastic leukemia 164
 Lymphocytes 413
- Mafosphamide 440
 Malignant melanoma 81
 Malignant mesothelioma 239
 MDL 72222 472
 Mechanism of action 199
 Medroxyprogesterone 101, 271
 Melanoma 157, 379
 Melphalan 379
 Mesna 111
 Metabolism 141, 342
 Metal complexes 301
- Methotrexate 60, 484
 Methotrexate toxicity 331
 Mice 106
 Mitomycin C 79, 243, 290
 Mitomycin C-resistant tumor 89
 Mitoxantrone 429, 477
 Monomethyl derivative 423
 Mononuclear cells 258
 Multidrug resistance 290, 445
 Myelocytic leukemia 151
 Myeloid leukemia 168
 Myelosuppression 13
 Myelotoxicity 226
 Mytomycin derivative 89
- Nafazatrom 326
 Nephrectomy 211
 Neurological deficit 329
 Neurotoxicity 226
 Neutropenia 253
 Nigericin 440
 Nimustine hydrochloride 20
 Nonlymphocytic leukemia 397
 Non-small-cell lung cancer 72, 251
- Ovarian carcinoma 389
 Ovarian tumors 301
- P388 cells 187
 Perfusion 279
 Pharmacodynamics 67, 147, 263, 373
 Pharmacokinetics 1, 55, 67, 205, 219, 234,
 367, 373, 397, 401, 406, 429, 451
 Pharmacology 308, 361
 Pharmacology of metabolites 8
 Phase II study 239
 Phase I study 131, 229, 258
 Phosphoramide mustard 1
 Pilot study 389
 Plasma 1
 Plasma concentration 20
 Platinum 301
 Platinum analogs 263
 Platinum pharmacology 72
 Porphyrin 187
 Preclinical 89, 194
 Preclinical study 361
 Prednimustine 477
 Protecting agents 111
 Protein binding 27
 Protein binding ACNU 20
- Psoralens 315
 Purine analogs 171
- Rabbits 125
 Radiosensitisier 55
 Reaction kinetics 111
 Recombinant interferon alpha-C 406
 Refractory testicular cancer 85
 Renal cortex 178
 Renal function 211
 Renal insufficiency 76, 234
 rG-CSF 253
 Rhodamine 123 205
 Rodent mammary tumours 271
 Ruthenium 301
- Salvage chemotherapy 85
 Salvage chemotherapy 161
 Slow-release 347
 Small-cell lung cancer 490
 Stability 295
 Stability of etoposide 354
 Sustained release 401
 Synergism 315
- Teniposide 85, 397, 487
 TEPA 373
- Tetrachloro (d,1trans)1,2-diaminocyclohexaneplatinum (IV) 335
- Tetraplatin 335
 Thiopurines 278
 Thiosulfate 111
 thio-TEPA 373
 Titanium 301
 Toremifene 8
 Toxicity 135, 335, 429
 Triazenes 342
 Triglycidylurazol 1,2,4- 361
 Trisomy 21 331
 Tumor 1, 106
 Tumor model 121
- Urogenital cancer 253
 UV 315
- Verapamil 413
 Vinblastine 251
 Vincristine 484
 VM-26 194
 VP-16 194
- Xenografts 278, 464

